Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Niraparib significantly improves outcomes for ovarian cancer patients

ESMO 2016

7 - 11 Oct 2016

Published: 8 Oct 2016

Views: 2178

Rating:

Save

Dr Mansoor Raza Mirza - Rigshospitalet, Copenhagen University Hospital, Denmark

Dr Mirza speaks to ecancer at ESMO 2016 about results from the NOVA trial of niraparib, a PARP inhibitor, to treat platinum sensitive recurrent ovarian cancer.

Dr Mirza describes the significant extension of progression free survival in all patient subgroups assessed through the trial, hailing it as a 'break through'.

The results were published simultaneously to the conference in the New England Journal of Medicine.

Video of the press conference is available here.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours

Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours ( Dr Jason Luke - University of Pittsburgh, Pittsburgh, USA )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Molecular profiling in prostate cancer: key challenges for clinical implementation

Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain

Molecular profiling in prostate cancer: key challenges for clinical implementation ( Dr Joaquin Mateo - Vall d’Hebron Institute of Oncology, Barcelona, Spain )

More from ecancer